Advisory Board
The Duke-Margolis Advisory Board is an essential resource for insights on health policy, and members provide counsel on the Institute's strategic direction and priorities. Duke-Margolis is overseen by Mary Klotman, the Executive Vice President for Health Affairs at Duke University, Dean of the Duke University School of Medicine, and Chief Academic Officer of Duke Health; and Duke University Provost Alec Gallimore, who also serves on the Duke-Margolis External Advisory Board chaired by Dr. Robert Margolis.
18 senior advisors serve on the advisory board, bringing experience from policy-relevant public and private sectors including healthcare payers, legislative, biomedical, foundation, and high technology. The Board’s advisory function will be served predominantly through participation in bi-annual face-to-face meetings, alternating between the Washington, DC and Durham, NC locations, but advisors may also provide occasional advice for particular initiatives.
Current members are:
Drew Altman is President and Chief Executive Officer of the Kaiser Family Foundation (KFF) and also is founding publisher of KFF Health News. He previously served as commissioner of the Department of Human Services for the state of New Jersey. Prior to that, Drew was Director of Health and Human Services at The Pew Charitable Trusts, Vice President of the Robert Wood Johnson Foundation, and served in a senior position in the Health Care Financing Administration in the Carter administration.
Drew earned his doctorate in political science at the Massachusetts Institute of Technology and completed his postdoctoral work at Harvard University before moving on to public service. He holds an honorary doctorate from the Morehouse School of Medicine. He is a member of the National Academy of Medicine, where he served on the Governing Committee.
David Brailer, MD, PhD - Capital Impact Council Member
David Brailer is the Chief Health Officer of The Cigna Group and Chairman of Health Evolution. Prior to this role, he founded Health Evolution and CareScience, and served as the nation’s first National Coordinator for Health Information Technology under President George W. Bush. David earned his MD from West Virginia University and his PhD in economics from The Wharton School. He became board certified in internal medicine after internship and residency at the Hospital of the University of Pennsylvania, where he practiced infectious diseases and HIV medicine. David was appointed a Charles A. Dana Fellow and a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania. He also taught for a decade at The Wharton School, where he founded the Wharton School health information technology program.
Bradley L. Campbell is the President and Chief Executive Officer and a member of the Board of Directors of Amicus Therapeutics, a global biotechnology company focused on developing and delivering drugs for rare diseases. He brings more than 20 years of experience in the Orphan Drug industry. Bradley joined Amicus in 2006 and was most recently the President and Chief Operating Officer responsible for the global commercialization of Galafold®. During his tenure, he also led the Business Development, Technical Operations, Market Access, Program Management, and Clinical Operations functions, among others.
Bradley currently serves on a number of Boards including Gennao Bio, the Alliance for Regenerative Medicine (ARM), and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals from 2016 until its successful acquisition by Lantheus Holdings in 2020, as well as ARYA Sciences Acquisition Corp III until its successful merger with Nautilus Biotechnology, Inc. in 2021.
Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a BA in Public Policy Studies from Duke University and an MBA from Harvard Business School.
Patrick Conway is Chief Executive Officer of Optum Rx, an integrated pharmacy care services organization. He previously served as CEO of Care Solutions, as President and CEO of Blue Cross and Blue Shield of North Carolina, as Deputy Administrator for Innovation and Quality at the Centers for Medicare and Medicaid Services, and as Director of the Center for Medicare and Medicaid Innovation and the agency’s Chief Medical Officer. Before joining CMS, he oversaw clinical operations and quality improvement at Cincinnati Children’s Hospital Medical Center. Patrick was elected to the National Academy of Medicine in 2014, received the President’s Senior Executive Distinguished Service Award, and was a White House Fellow from 2007 to 2008.
Susan Dentzer is President and Chief Executive Officer of America’s Physician Groups, the nonprofit organization representing more than 360 large physician groups focused on patient-centered, coordinated, and integrated health care that is accountable for both costs and quality. She is an elected member of the National Academy of Medicine and the Council on Foreign Relations and is a fellow of the National Academy of Social Insurance and the Hastings Center. Susan earned a master’s degree in health care delivery from Dartmouth, where she also is a trustee emerita. She formerly chaired the Dartmouth’s Board of Trustees as well as the board of Dartmouth Health, Research!America, and the International Rescue Committee (IRC). Susan currently serves on the advisory board of IRC, the Center for Global Health Equity at Dartmouth, and the Philip R. Lee Institute for Health Policy Studies at the University of California - San Francisco (UCSF).
As Chairman of Oracle Health, David Feinberg is committed to making health care more accessible, affordable and equitable. Previously, David served as president and CEO of Cerner, now Oracle Health, where he led teams delivering tools and technology to improve the patient and caregiver experience. Prior to these roles, he served as Vice President of Google Health as well as president and CEO of both UCLA Health and Geisinger Health.
Alec D. Gallimore is the Provost and Chief Academic Officer of Duke University and Alfred J. Hooks E ’68 Distinguished Professor in the Thomas Lord Department of Mechanical Engineering & Materials Science of the Pratt School of Engineering. Prior to his appointment at Duke in 2023, Dr. Gallimore held multiple leadership roles over his 30+ year career at the University of Michigan, including the Robert J. Vlasic Dean of Engineering, associate dean for academic affairs, associate dean for research and graduate education, and associate dean at the Horace H. Rackham School of Graduate Studies.
Before the start of his career in academia, he solidified his credentials as a rocket scientist first at Rensselaer (RPI), where he received his BS degree in aeronautical engineering, and then at Princeton, where he received his MA and PhD degrees in aerospace engineering with a focus on plasma physics and advanced spacecraft propulsion.
Dr. Rebekah Gee is the CEO/Founder of Nest Health and an Obstetrician/Gynecologist. Through an innovative care model, Nest addresses generational drivers of poor health by providing primary, behavioral, and social care through house calls, virtual visits, and wraparound services. Rebekah previously served as Secretary of the Louisiana Department of Health where she oversaw half the state budget and the implementation of Medicaid expansion. She has an extensive background in quality improvement, has served on the boards of the National Quality Forum and NCQA, and currently serves on the board of the Institute for Healthcare Improvement.
Before her time as Secretary, Rebekah served as the Medicaid Medical Director for Louisiana Medicaid, the Medical Director for Title V, and directed Louisiana’s Birth Outcomes Initiative. In 2017, her exceptional contributions led to her election to the National Academy of Medicine. She currently serves on the medical advisory board for 3D systems and has previously served in a similar role for SelectQuote.
Blake Goodner - Capital Impact Council Member
Blake Goodner is a founding member of Bridger Management and Bridger Healthcare. Prior to joining Bridger, Blake was a Research Associate at Tiger Management, LLC, where he specialized in health care investments. From 1996 to 1998, he was an Investment Banking Financial Analyst in the health care group at Morgan Stanley & Co. Blake graduated from Duke University in 1996. He was a member of the Duke University Trinity Board of Visitors and now is a member of Duke Financial Economics Board as well as a founder of the Duke University Goodner Equity Research Project economics class. He is a member of the board of directors of multiple private health care companies and also performs strategic advisory work.
Frederick Isasi is the former executive director of Families USA (FUSA), a nonprofit, nonpartisan health care advocacy organization established to ensure the best health and health care are equally accessible and affordable to all. Before joining FUSA, he was a division director at the bipartisan National Governors Association and vice president and founder of the health policy department at the Advisory Board Company. He also previously served as senior legislative counsel on health care for U.S. Senator Jeff Bingaman (D-NM).
As Managing Member of KingMan LLC, David P. King provides strategic consulting services for stakeholders across the health care system. His areas of focus include expanding access to care, improving quality of care, lowering cost of care, improving the patient experience and fostering innovation across health care. Previously, David was an Operating Partner of Healthcare at Pritzker Private Capital and served as Chairman, CEO, and President of LabCorp. In addition to his consulting practice, he currently serves on numerous boards, including Privia Health, LGC Group, and Novant Health.
A nationally recognized leader in academic medicine, Mary E. Klotman, MD, is executive vice president for health affairs at Duke University, dean of the Duke University School of Medicine, and chief academic officer for Duke Health. Klotman was appointed as Duke’s first executive vice president for health affairs in June 2023 and assumed her new role on July 1, 2023. She was named dean of the School of Medicine in January 2017 and was appointed to a second five-year term in 2022. Prior to her appointment as dean, Klotman served with distinction as chair of the Department of Medicine in the Duke University School of Medicine for seven years.
Klotman earned her undergraduate and medical degrees from Duke University. She completed her internal medicine residency and a fellowship in Infectious Diseases in the Department of Medicine at Duke before joining the faculty as assistant professor of medicine. She joined the National Institutes of Health in 1991, where she was a member of the Public Health Service and trained and worked in the Laboratory of Tumor Cell Biology under the direction of Robert C. Gallo, MD.
Klotman is past president of the Association of Professors of Medicine and the Association of American Physicians. She was elected to membership in the Academy of Medicine in 2014 and the American Academy of Arts & Sciences in 2021. Klotman is a former president of the Duke Medical Alumni Association and received a Duke University School of Medicine Distinguished Alumni Award in 2015.
Esther Krofah is the executive vice president of Milken Institute (MI) Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives. Most recently, Krofah was the director of public policy at GlaxoSmithKline (GSK), where she led engagement with the US Department of Health and Human Services (HHS) and relevant executive branch agencies on broad healthcare policy issues. Prior to GSK, Krofah was a deputy director of HHS’ Office of Health Reform. She also served as program director at the National Governors Association healthcare division and worked in consulting at Deloitte Consulting LLP. Krofah received a BA from Duke University and a Master in Public Policy from the Harvard University John F. Kennedy School of Government.
Michelle McMurry-Heath, MD, PhD
Former President and CEO, BIO
Jessica L. Mega, MD, MPH is a Cardiologist at Stanford and Co-Founder of Alphabet's Verily. She is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors at Research!America, Duke-Margolis Institute for Health Policy, and Duke’s i-Cubed Center for Clinical Research Innovation. Previously, as a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, she led large, international, randomized trials evaluating novel therapies. She also directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding.
Former President, National Partnership for Women & Families
Peter R. Orszag is Chief Executive Officer of Lazard, the preeminent global financial advisory and asset management firm. He has led the firm and been a Board Director since October 2023. Prior to becoming Chief Executive Officer, Peter was CEO of Financial Advisory, leading Lazard's advisory businesses serving companies and governments across the globe. He was previously the firm's Head of North American Mergers & Acquisitions and Global Co-Head of Healthcare. Peter joined Lazard as Vice Chairman of Investment Banking in May 2016. In the Obama Administration, he served as the Director of the Office of Management and Budget, and before that, as the Director of the Congressional Budget Office.
Amir Dan Rubin, MBA, MHSA - Capital Impact Council Member
Amir Dan Rubin currently serves as CEO & Founding Managing Partner of Healthier Capital, a venture capital firm focused on health care innovation. He previously served as Chair & CEO of the technology-powered primary care company, One Medical, which he took public in 2020 and sold to Amazon in the beginning of 2023. Prior to that, Amir served as an EVP at UnitedHealth Group and its Optum division. Prior to that, he served as CEO at Stanford University’s health system, COO at UCLA’s health system, COO at SUNY Stony Brook’s health system, and in leadership roles at Memorial Hermann’s health system.
Marc Samuels, JD, MPH - Capital Impact Council Member
Marc B. Samuels is CEO of ADVI Health, a strategic consulting partner to the health care and life sciences ecosystem solving complicated problems in health care with data-informed commercialization, market access, and policy expertise. Marc started his career serving both President George H.W. Bush in the White House Council on Competitiveness and the White House Office of Policy Development; and then-Texas Governor George W Bush in the Texas Health and Human Services Commission, and Governor’s Office of Policy. Marc was also a partner at HillCo Partners, managing partner and founder of HillCo HEALTH, and co-founder and principal of The Health Policy Group. He currently serves on the boards of the NCCN Foundation and UCSF Rosenman Institute in addition to Duke-Margolis.
*Duke-Margolis is a client of ADVI Health and consults with its subject matter experts on a range of technical health policy topics.
Barbara Wachsman is the Senior Advisor at Frazier Healthcare Partners and sits on the American Board of Medical Specialties. Her expertise lies in developing direct relationships between self-funded employers and physicians. Previously, she was the Director of Strategy and Engagement for Enterprise Benefits at The Walt Disney Company. Before joining Disney, Barbara spent close to 30 years in senior management positions with two international benefit consulting firms and served as a Principal with Arthur Andersen, where she ran the West Regional Human Capital practice.
